Overview of randomisation and patient characteristics at baseline (20th April 2014)
| Baseline characteristics | |
|---|---|
| Inclusion and randomisation | |
| Screened | 317 |
| Randomised | 177 |
| Characteristics (%) | |
| Ischaemic heart disease | 65 |
| Diabetes | 35 |
| NYHA classes (%) | |
| 1 | 38 |
| 2 | 46 |
| 3 | 16 |
| 0 | 0 |
| Smoking (%) | |
| Currently | 20 |
| Previous | 52 |
| Never | 28 |
| Treatment (%) | |
| ACE inhibitor | 64 |
| ARB | 30 |
| Aspirin | 63 |
| β-Blocker | 90 |
| Statin | 81 |
| Safety | |
| Adverse events | 224 |
| Serious adverse events | 23 |
ARB, angiotensin 2 receptor blocker.